News

September 20, 2018September 20, 2018

FDA Gives Green Light to 2 Trials for AB-PA01, Potential Therapy Against P. aeruginosa Infections

cystic fibrosis, News

The U.S. Food and Drug Administration gave positive feedback to the design of AmpliPhi Biosciences’ two proposed clinical trials of its Pseudomonas aeruginosa-targeting treatment candidate AB-PA01, the company announced ... Read more

September 19, 2018September 19, 2018

Electronic Nose Offers Easy, Accurate Test for CF in Children, Pilot Study Finds

cystic fibrosis, News

A new electronic nose, called Aeonose, was seen to be a feasible, accurate and easy-to-use diagnostic test for cystic fibrosis (CF) in children and adolescents, a small pilot study ... Read more

September 18, 2018September 18, 2018

Researchers Find Way to Improve Antibiotics’ Efficacy Against Pseudomonas aeruginosa

cystic fibrosis, News

Blocking superoxide dismutase, the enzyme that responds to stress, in Pseudomonas aeruginosa bacteria improves antibiotics’ efficacy, a Canadian study reported. The study, “Superoxide dismutase activity confers (p)ppGpp-mediated antibiotic tolerance to ... Read more

September 14, 2018September 14, 2018

Orkambi Eases Flares Even in CF Patients Slow to Show Improvement in Lung Health, Trial Data Show

cystic fibrosis, News

Cystic fibrosis patients who failed to show early improvements in lung function while being treated with Orkambi (lumacaftor/ivacaftor) still experienced fewer pulmonary exacerbations than those given a placebo in Phase ... Read more

September 13, 2018September 13, 2018

Mutations Linked to Severe CF Seen to Affect Health of Heart’s Left Ventricle in Study

cystic fibrosis, News

Mutations in the CFTR gene that associate with severe disease can also lead to cardiac problems — specifically, the development of subclinical left ventricular dysfunction — in cystic fibrosis patients, ... Read more

September 11, 2018September 12, 2018

Two Phase 3 Trials of Vertex’s Triple Combination Therapy with VX-659 Are Fully Enrolled

cystic fibrosis, News

Vertex Pharmaceuticals has completed enrollment for two Phase 3 studies testing the triple combination therapy of its new CFTR corrector VX-659 together with tezacaftor (VX-661) and Kalydeco (ivacaftor) in patients with cystic ... Read more

September 10, 2018September 10, 2018

Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients

cystic fibrosis, News

Editor’s Note: This is the second of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we detail the steps that made three disease-modifying oral ... Read more

September 7, 2018September 7, 2018

Reimbursement Agreement Includes Orkambi in Public Health Plan for CF Patients in Australia

cystic fibrosis, News

Beginning Oct. 1, the cystic fibrosis (CF) targeted therapy Orkambi (lumacaftor/ivacaftor) will be included on Australia’s Pharmaceutical Benefits Scheme. The Australian government’s decision resulted from the completion of an ... Read more

September 6, 2018September 6, 2018

Australian Museum Eureka Prize Given CF Research Team for Work on Bacteria’s Spread Among Patients

cystic fibrosis, News

A research team at The University of Queensland was honored for its work on the spread of bacteria among cystic fibrosis patients, being named a winner of this year’s Australian Museum Eureka Prizes. The prizes ... Read more

September 5, 2018September 5, 2018

Vertex, Genomics Team Up in Quest for Genetics-based, Precision Medicines

cystic fibrosis, News

Vertex Pharmaceuticals and Genomics announced a three-year collaboration to better understand genetic variations and their effect on clinical outcomes of diseases with unmet therapeutic needs, including cystic fibrosis. The collaboration ... Read more

Pin It on Pinterest